PL3423087T3 - Skojarzona terapia przeciwnowotworowa - Google Patents

Skojarzona terapia przeciwnowotworowa

Info

Publication number
PL3423087T3
PL3423087T3 PL17709038.8T PL17709038T PL3423087T3 PL 3423087 T3 PL3423087 T3 PL 3423087T3 PL 17709038 T PL17709038 T PL 17709038T PL 3423087 T3 PL3423087 T3 PL 3423087T3
Authority
PL
Poland
Prior art keywords
cancer therapy
combination anti
combination
cancer
therapy
Prior art date
Application number
PL17709038.8T
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of PL3423087T3 publication Critical patent/PL3423087T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17709038.8T 2016-03-04 2017-03-03 Skojarzona terapia przeciwnowotworowa PL3423087T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Publications (1)

Publication Number Publication Date
PL3423087T3 true PL3423087T3 (pl) 2024-05-20

Family

ID=58231605

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17709038.8T PL3423087T3 (pl) 2016-03-04 2017-03-03 Skojarzona terapia przeciwnowotworowa

Country Status (13)

Country Link
US (2) US20190343940A1 (pl)
EP (2) EP4316517A3 (pl)
JP (3) JP2019507180A (pl)
DK (1) DK3423087T3 (pl)
ES (1) ES2965009T3 (pl)
FI (1) FI3423087T3 (pl)
HR (1) HRP20240052T1 (pl)
HU (1) HUE064857T2 (pl)
LT (1) LT3423087T (pl)
PL (1) PL3423087T3 (pl)
PT (1) PT3423087T (pl)
SI (1) SI3423087T1 (pl)
WO (1) WO2017149150A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
KR20180069903A (ko) 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
WO2017149150A1 (en) * 2016-03-04 2017-09-08 Io Biotech Aps Combination therapy against cancer
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
CA3070774A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
WO2019102265A1 (en) * 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
JP2021504336A (ja) * 2017-11-24 2021-02-15 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化
EP3755720A1 (en) 2018-02-21 2020-12-30 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
GB202103673D0 (en) * 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
JP2024522256A (ja) * 2021-05-17 2024-06-12 ウィスコンシン アラムニ リサーチ ファンデーション 免疫寛容を誘導するための合成タンパク質
TW202345864A (zh) * 2022-02-18 2023-12-01 美商現代公司 編碼檢查點癌症疫苗之ｍＲＮＡ及其用途
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO2008100562A2 (en) * 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
SI2280721T1 (en) * 2008-04-17 2018-02-28 Io Biotech Aps C/O Cobis Indoleamine 2, 3-dioxygenase based immunotherapy
BR112014009526B8 (pt) 2011-10-17 2023-01-17 Herlev Hospital Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
KR20160108568A (ko) * 2014-02-04 2016-09-19 인사이트 코포레이션 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
CA2947687C (en) * 2014-05-30 2021-07-06 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
WO2017149150A1 (en) 2016-03-04 2017-09-08 Io Biotech Aps Combination therapy against cancer

Also Published As

Publication number Publication date
JP7785817B2 (ja) 2025-12-15
EP4316517A3 (en) 2024-05-29
WO2017149150A1 (en) 2017-09-08
HRP20240052T1 (hr) 2024-03-29
PT3423087T (pt) 2023-12-28
DK3423087T3 (da) 2023-12-18
JP7417645B2 (ja) 2024-01-18
ES2965009T3 (es) 2024-04-10
JP2022068348A (ja) 2022-05-09
US20190343940A1 (en) 2019-11-14
FI3423087T3 (fi) 2023-12-15
JP2024045180A (ja) 2024-04-02
EP3423087A1 (en) 2019-01-09
SI3423087T1 (sl) 2024-03-29
LT3423087T (lt) 2024-01-25
EP4316517A2 (en) 2024-02-07
EP3423087B1 (en) 2023-11-15
HUE064857T2 (hu) 2024-04-28
JP2019507180A (ja) 2019-03-14
US20220257741A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
EP3463464A4 (en) ASSOCIATION TREATMENT
PL3423087T3 (pl) Skojarzona terapia przeciwnowotworowa
EP3368656A4 (en) TARGETED CANCER THERAPY
EP3563835A4 (en) NEW EXOSOME-BASED ANTI-CANCER AGENT
DK3328880T3 (da) Terapeutiske midler
EP3291824A4 (en) ANTIMICROBIAL THERAPY
DK3240801T3 (da) Kombinationstumorimmunterapi
EP3499651A4 (en) Connector
PL3458052T3 (pl) Leczenie skojarzone nowotworu
EP3471539A4 (en) SIGNALING PROCESSING WITH KLRG1
EP3424940A4 (en) Radiolabeled drug
EP3345041C0 (en) BIDIRECTIONAL COLLIMATOR
EP3297102A4 (en) Connector
EP3413927A4 (en) CANCER THERAPY
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
EP3246047C0 (en) COMBINATION MEDICATION
EP3512553A4 (en) KLRG1 EXHAUST THERAPY
EP3437644A4 (en) MEDICINE
EP3362091A4 (en) COMBINATION THERAPY
EP3541931A4 (en) COMBINED FRACTAL TREATMENT
EP3256115A4 (en) COMBINATION CANCER THERAPY
EP3527216A4 (en) Medicine
DK3432901T3 (da) Sekventiel antikræftbehandling